300
Participants
Start Date
August 15, 2019
Primary Completion Date
October 20, 2022
Study Completion Date
November 7, 2022
89Zr-girentuximab
Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
Institute Jules Bordet, Brussels
Royal North Shore Hospital, St Leonards
Macquarie University Hospital, Sydney
Victorian Comprehensive Cancer Centre, Melbourne
University Hospital Leuven (UZ Leuven), Leuven
Austin Health, Heidelberg
Royal Brisbane and Women's Hospital, Herston
Princess Alexandra Hospital, Woolloongabba
Memorial Sloan Kettering Cancer Center, New York
Advanced Molecular Imaging & Therapy, LLC, Glen Burnie
Johns Hopkins University Hospital, Baltimore
Emory University, Atlanta
CHU de Bordeaux, Groupe hospitalier Pellegrin, Bordeaux
Istanbul Training and Research Hospital, Istanbul
Istanbul University Cerrahpasa Medical Faculty, Istanbul
Nantes University Hospital Hotel-Dieu, Nantes
Barbara Ann Karmanos Cancer Hospital, Detroit
CHRU de Nancy, Hopitaux de Brabois, Nancy
Washington University St Louis, St Louis
University of California, Los Angeles Campus,, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
SEATTLE CANCER CARE ALLIANCE, University of Washington, Seattle
Cabrini Hospital, Melbourne
Centre De Recherche Centre hospitalier de l/Universite de Montreal (CrCHUM ), Montreal
Jewish General Hopsital, Montreal
CHU de Québec - Université Laval - L'Hôtel-Dieu de Québec, Québec
Netherlands Cancer Institute, Amsterdam
Radboud University Medical Centre, Nijmegen
Ankara University Medical Faculty Hospital, Ankara
Hacettepe University Faculty of Medicine, Ankara
Royal Free London NHS Foundation Trust, London
Telix Pharmaceuticals (Innovations) Pty Limited
INDUSTRY